Latest Sunitinib Stories
NEW YORK, Dec. 2, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease.
NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
A UC Irvine oncologistâ€™s work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer.
Cancer drug now approved to treat rare genetic disorder SILVER SPRING, Md., Nov. 1, 2010 /PRNewswire-USNewswire/ -- The U.S.
BURLINGTON, Mass., Oct.
New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient's sex life.
NEW YORK, Oct. 7 /PRNewswire-FirstCall/ -- Pfizer Oncology will present new data across its portfolio representing novel approaches to researching treatments for patients with rare and difficult-to-treat cancers.
CHICAGO, Oct. 1 /PRNewswire/ -- Argos Therapeutics announced that its Arcelis immunotherapy for renal cell carcinoma (RCC), AGS-003, demonstrated favorable progression-free survival (PFS) and safety in combination with sunitinib, based upon updated results from an ongoing Phase 2 trial.
NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Pfizer Inc.
- The governor of a province or people.